Suprachoroidal injection is a method of delivering medication into a thin, naturally occurring space inside the eye, positioned between the white outer wall (the sclera) and the blood-vessel-rich layer beneath it (the choroid). This route targets the back of the eye more directly than the standard intravitreal injection that most retinal patients are familiar with, and in 2021 it became the basis of the first FDA-approved therapy for macular edema caused by uveitis. The approach is newer than intravitreal injection, the technology is still evolving rapidly, and its list of potential uses is growing.
Where the Drug Actually Goes
The suprachoroidal space is what eye specialists call a “potential space,” meaning the two tissue layers that define it are normally pressed together with no appreciable gap between them. Once fluid is injected, the layers separate and the space opens up, allowing the drug to flow along the curved inner surface of the eye toward the back, where the retina and choroid are located.1PubMed Central. The suprachoroidal space as a route of administration to the posterior segment of the eye Imaging with optical coherence tomography (OCT) has confirmed this expansion and the directional flow of fluid from the injection site toward the posterior pole in both animal studies and human clinical trials.2Retina. Suprachoroidal Space Injection Technique: Expert Panel Guidance
Cadaveric studies give a concrete picture of how the fluid spreads. When about half of a typical volume (around 50 microliters) is injected, the fluid covers roughly 11% of the suprachoroidal space. A full 100-microliter injection pushes that to about 22%, and the fluid continues to spread over the following minutes, reaching roughly a third of the space by 20 minutes after injection starts. The fluid tends to move sideways around the injection site first, staying in the front of the eye before migrating toward the back.3Translational Vision Science & Technology. Evaluation of Suprachoroidal Injection in Cadaveric and Preclinical Models
Why Not Just Use a Standard Intravitreal Injection
The intravitreal route, where medication is injected into the gel-filled center of the eye, is the workhorse of modern retinal treatment. It works, but the drug has to diffuse through the vitreous humor and several tissue layers before reaching the choroid and retinal pigment epithelium, where many diseases are centered. Suprachoroidal injection effectively bypasses all of that. Studies have found that drug concentrations in the choroid are higher after suprachoroidal delivery than after intravitreal delivery, making it especially appealing for diseases that originate in or near the choroid.4PubMed. Suprachoroidal Drug Delivery for VEGF Suppression in Wet AMD and Other Diseases With Choroidal Neovascularization Drugs delivered this way reach higher baseline concentrations in the target tissue layers than the same drugs given intravitreally.5PubMed Central. Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases
There is a trade-off, though. Water-soluble molecules clear from the suprachoroidal space faster than they do from the vitreous, probably because the choroid is packed with blood vessels that whisk soluble drugs away quickly.6PubMed Central. Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases Work in an ex vivo pig eye model confirmed that choroidal blood flow reduces tissue drug levels of water-soluble drugs, acting as an early clearance mechanism.7PubMed. Effect of choroidal perfusion on ocular tissue distribution after intravitreal or suprachoroidal injection in an arterially perfused ex vivo pig eye model This means the route works best with drugs that are formulated as suspensions or particles rather than simple solutions, because those resist being swept away before they can act.
The Steroid Eye Pressure Question
One of the biggest practical headaches with intravitreal steroid injections is a rise in eye pressure. Elevated intraocular pressure (IOP) is a well-known side effect of steroids placed inside the eye, and it can threaten the optic nerve if it stays high long enough. The suprachoroidal route appears to sidestep much of this problem. In a head-to-head comparison of triamcinolone acetonide given suprachoroidally versus intravitreally for diabetic macular edema, the suprachoroidal group actually showed a reduction in IOP at the one-week follow-up, while the intravitreal group experienced pressure spikes at later visits.8Journal of Rawalpindi Medical College. Suprachoroidal Versus Intravitreal Injection of Triamcinolone Acetonide As Primary Treatment For Diabetic Macular Edema
Another comparative trial found that significant IOP elevation (10 mmHg or more above baseline) occurred in only a small fraction of eyes across both routes, and cataract progression rates were similar between the two groups.9PubMed Central. Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema The lower pressure-elevation risk is a meaningful advantage for patients who need repeated steroid injections and are already at risk for glaucoma. It also makes the suprachoroidal route attractive in situations where the disease calls for a steroid but pressure concerns have historically limited how aggressively a doctor could treat.
What Diseases It Treats Today
The landmark indication is macular edema associated with noninfectious uveitis, an inflammatory swelling of the central retina caused by the body’s own immune system attacking the eye. In the phase 3 trial that led to FDA approval, about 47% of patients receiving suprachoroidal triamcinolone acetonide gained 15 or more letters on the standard eye chart by 24 weeks, compared with about 17% of controls. Retinal thickness, measured by OCT, dropped by an average of roughly 164 micrometers in the treatment group versus about 19 micrometers in controls.10PubMed Central. Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies That improvement was both rapid (most of the swelling reduction happened within the first four weeks) and sustained through the full six months of the trial.11PubMed. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial
The same steroid has been studied in diabetic macular edema and other chorioretinal diseases. Reviews of the available data have found that suprachoroidal triamcinolone consistently reduces macular thickness and improves visual acuity across these conditions, with a satisfactory safety profile overall.12PubMed Central. Suprachoroidal Triamcinolone Acetonide Injection to Treat Macular Edema: A Review While the FDA approval currently covers uveitic macular edema, these other uses are actively being studied and some clinicians use the technique off-label for them.
How the Injection Is Actually Performed
The procedure uses a specially designed microneedle rather than a conventional hypodermic needle. The microneedle is short enough that it penetrates the full thickness of the sclera but stops before it reaches the retina. Because the sclera is only about 500 to 700 micrometers thick in most of the regions where injections are performed, precise needle length matters. Drugs can be delivered safely via hollow microneedles fitted to match the approximate scleral thickness.13PubMed Central. Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases The injection is performed as an outpatient procedure, similar in logistics to a standard intravitreal injection.
Newer device designs are pushing toward greater precision. One platform under development uses a curved, scleral-depressor-inspired shape with a “side-firing” needle, allowing the surgeon to reach the posterior and equatorial regions of the globe more easily while visualizing the injection site through an indirect ophthalmoscope.142026 Design of Medical Devices Conference. Design of a Precision Ocular Injector for Targeted, Minimally Invasive Drug Delivery to the Posterior Suprachoroidal Space Another platform incorporates real-time OCT imaging so that the surgeon can watch the needle enter the sclera, confirm it has reached the suprachoroidal space, and see the characteristic tissue separation as the fluid is delivered. This helps prevent the needle from accidentally advancing into the retina.15PubMed Central. A Low-Cost, Tunable Suprachoroidal Injection Platform with Real-Time OCT Guidance for Gene Therapy Delivery These are still at the preclinical and engineering-evaluation stages, but they signal where the field is heading: less guesswork, more feedback during the procedure itself.
Controlling Where the Drug Ends Up
One of the less obvious challenges with suprachoroidal injection is directing the drug to a specific region of the eye rather than letting it spread diffusely. Researchers have been experimenting with formulation tricks to solve this. When drug particles are injected in plain saline, they spread over roughly 29 to 42% of the suprachoroidal space immediately. Adding hyaluronic acid to create a moderately thick fluid can push that spread to cover nearly the entire space, which is useful if you want widespread exposure. Conversely, using strongly thickened polymer solutions can confine the particles to as little as 8 to 20% of the space, keeping them concentrated near the injection site. That localized distribution held relatively stable over two months in animal studies.16PubMed Central. Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles
A separate approach uses a two-step injection: first a particle suspension, then a swelling hydrogel behind it that physically pushes the particles toward the back of the eye. Tuning the ratio of particle-solution thickness to hydrogel thickness changes how far back the drug travels. The best combination in one study pushed about 70% of the particles more than 3 millimeters from the injection site toward the posterior pole.17PubMed Central. Retina Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing These are still preclinical strategies, but they illustrate why formulation science is just as important as device engineering for making suprachoroidal delivery work across different diseases and drug types.
Gene Therapy Through the Suprachoroidal Space
The growing excitement around gene therapy for inherited retinal diseases has opened another frontier for suprachoroidal delivery. The current gold standard for retinal gene therapy, subretinal injection, requires vitreoretinal surgery and creates a temporary retinal detachment at the injection site. Suprachoroidal injection avoids both of those, which makes it attractive as a less invasive alternative if it can get the gene-carrying viral vectors into the right cells.
Animal studies suggest it can. In rats, suprachoroidal delivery of AAV8 carrying a fluorescent reporter gene produced expression throughout the choroid, retinal pigment epithelium, and outer retina extending around the entire circumference of the eye, a much wider distribution than what subretinal injection typically achieves.18JCI Insight. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression A broader comparison of five different AAV serotypes across three delivery routes found that suprachoroidal injection mirrored the cell-type targeting pattern of subretinal delivery for every serotype tested, but with wider coverage and greater transduction of the outer nuclear layer, the retinal layer that contains the photoreceptors.19PubMed Central. Retinal Tropism and Transduction of Adeno-Associated Virus Varies by Serotype and Route of Delivery (Intravitreal, Subretinal, or Suprachoroidal) in Rats
These findings are in rodents, and the jump from rat eyes to human eyes is a big one. Human scleral and choroidal anatomy differ enough that distribution patterns may not translate directly. But the prospect of achieving gene therapy-level transduction without surgery is compelling enough that multiple groups are actively working on translating the approach into clinical trials. The OCT-guided injection platforms described earlier were developed specifically with gene therapy payloads in mind, because precise delivery is even more critical when the “drug” is a permanent genetic modification.
Beyond Steroids and Genes
The suprachoroidal route is also being explored for anti-VEGF therapy, the class of drugs that currently dominates treatment of wet age-related macular degeneration (AMD). The rationale is that neovascular AMD and other diseases involving choroidal blood vessel overgrowth originate in the choroid itself, so delivering anti-VEGF agents directly to that tissue could be more efficient than putting them in the vitreous and waiting for diffusion. Early clinical and preclinical results with suprachoroidal VEGF-targeting therapies have been promising, though more work is needed to firmly establish both safety and efficacy in this space.20PubMed. Suprachoroidal Drug Delivery for VEGF Suppression in Wet AMD and Other Diseases With Choroidal Neovascularization
One candidate that has progressed the furthest is axitinib, a tyrosine kinase inhibitor that blocks VEGF signaling along with other growth-factor pathways. In a phase I/IIa dose-escalation trial, suprachoroidal axitinib suspension was well tolerated at doses up to 1.0 milligram, with patients maintaining stable visual acuity and retinal thickness. A majority of patients followed for six months did not need rescue injections of aflibercept, a standard intravitreal anti-VEGF drug, suggesting the suprachoroidal approach may reduce treatment burden.21Ophthalmology Science. Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial Reducing the number of injections patients need per year would be a meaningful quality-of-life improvement for people with wet AMD, who currently face monthly or bimonthly intravitreal injections indefinitely.
What the Procedure Costs
Because suprachoroidal triamcinolone for uveitic macular edema was a first-in-class therapy when approved, there was genuine uncertainty about whether it would be cost-effective compared with the alternatives, which in this case essentially meant best supportive care without a targeted treatment. A formal cost-effectiveness analysis found an incremental cost-effectiveness ratio of about $28,500 per quality-adjusted life-year gained. The wholesale acquisition cost of the drug came in well below standard willingness-to-pay thresholds used in U.S. health economics. At the commonly cited $100,000 threshold, the drug’s cost sat about 56% below the line, meaning the treatment offers solid value for money by conventional standards.22PubMed. Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis That analysis used data from the Medicare and commercial payer perspectives, so it is directly relevant to U.S. patients. How the economics shift as new suprachoroidal therapies reach the market, especially more expensive gene therapies, remains an open question.
Acute Safety Considerations
Injecting anything into a confined space inside the eye naturally raises the question of pressure spikes. Animal studies have confirmed that suprachoroidal injection does cause a transient, acute rise in IOP, and larger injection volumes produce larger spikes.23PubMed. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model In rabbit eyes, a 50-microliter injection was well tolerated, with the pressure elevation resolving quickly. The key distinction from steroid-related IOP problems is that these acute spikes are mechanical and brief, caused by the additional volume rather than by a drug effect on the eye’s fluid drainage. The longer-term steroid-related pressure rise that plagues intravitreal steroid users appears to be less pronounced with the suprachoroidal route, as discussed earlier.
Across clinical trials, the overall safety profile has been described as satisfactory, with no major unexpected adverse events emerging from the injection route itself. Suprachoroidal injection has demonstrated wide distribution of injected agents and safety as an outpatient procedure compared with other ocular injection methods.24Elsevier / American Journal of Ophthalmology. Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases The most commonly reported issues in trials have been mild, including transient eye pain at the injection site and brief increases in intraocular pressure that resolved without treatment. As with any injection into the eye, infection (endophthalmitis) is a theoretical risk, though it has been rare in the published data.
The Formulation Problem That Nobody Talks About
Much of the public attention around suprachoroidal injection focuses on devices and diseases, but the real engineering bottleneck may be formulation. A drug that dissolves completely in water will be whisked away by choroidal blood flow within hours, far too quickly to be therapeutic for chronic conditions. A particle suspension that is too thick will clump near the injection site instead of reaching the posterior pole where most retinal diseases are concentrated. And a suspension calibrated for one scleral thickness may behave differently in a patient whose sclera is thinner or thicker than average.
This is why so much preclinical work has gone into understanding how viscosity, particle size, and polymer chemistry interact inside the suprachoroidal space. The hydrogel-pushing approach and the hyaluronic-acid spreading studies described above are two examples of a broader effort to develop formulations that give clinicians predictable drug distribution. For gene therapy, the stakes are even higher: a viral vector that ends up concentrated in one quadrant of the eye may produce patchy gene expression, leaving parts of the retina untreated. Getting the formulation right is, in a real sense, as important as getting the drug right.